Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
CONCLUSIONS: Irbesartan could be used in combination with chemotherapy to improve the therapeutic efficacy in PDAC patients with high levels of c-Jun expression. Irbesartan effectively inhibited chemotherapy resistance by suppressing the Hippo/YAP1/c-Jun/stemness/iron metabolism axis. Based on our findings, we are designing an investigator-initiated phase II clinical trial on the efficacy and safety of irbesartan plus a standard gemcitabine/nab-paclitaxel regimen in the treatment of patients with advanced III/IV staged PDAC and are hopeful that we will observe patient benefits.PMID:37143164 | PMC:PMC10157938 | DOI:10.1186/...
Source: Clinical Genitourinary Cancer - May 4, 2023 Category: Cancer & Oncology Authors: Tianxing Zhou Yongjie Xie Xupeng Hou Weiwei Bai Xueyang Li Ziyun Liu Quan Man Jingyan Sun Danqi Fu Jingrui Yan Zhaoyu Zhang Yifei Wang Hongwei Wang Wenna Jiang Song Gao Tiansuo Zhao Antao Chang Xiuchao Wang Hongxia Sun Xiufeng Zhang Shengyu Yang Chongbiao Source Type: research
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
CONCLUSIONS: Irbesartan could be used in combination with chemotherapy to improve the therapeutic efficacy in PDAC patients with high levels of c-Jun expression. Irbesartan effectively inhibited chemotherapy resistance by suppressing the Hippo/YAP1/c-Jun/stemness/iron metabolism axis. Based on our findings, we are designing an investigator-initiated phase II clinical trial on the efficacy and safety of irbesartan plus a standard gemcitabine/nab-paclitaxel regimen in the treatment of patients with advanced III/IV staged PDAC and are hopeful that we will observe patient benefits.PMID:37143164 | PMC:PMC10157938 | DOI:10.1186/...
Source: Clinical Breast Cancer - May 4, 2023 Category: Cancer & Oncology Authors: Tianxing Zhou Yongjie Xie Xupeng Hou Weiwei Bai Xueyang Li Ziyun Liu Quan Man Jingyan Sun Danqi Fu Jingrui Yan Zhaoyu Zhang Yifei Wang Hongwei Wang Wenna Jiang Song Gao Tiansuo Zhao Antao Chang Xiuchao Wang Hongxia Sun Xiufeng Zhang Shengyu Yang Chongbiao Source Type: research
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance. (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - May 4, 2023 Category: Cancer & Oncology Authors: Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyun Liu, Quan Man, Jingyan Sun, Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yifei Wang, Hongwei Wang, Wenna Jiang, Song Gao, Tiansuo Zhao & hellip; Tags: Research Source Type: research
Metabolomics to study the sublethal effects of diazepam and irbesartan on glass eels (Anguilla anguilla)
Aquat Toxicol. 2023 Apr 26;259:106547. doi: 10.1016/j.aquatox.2023.106547. Online ahead of print.ABSTRACTSince glass eels are continuously exposed to contamination throughout their migratory journey in estuaries, to a certain extent the fall in the population of this endangered species might be attributed to this exposure, which is especially acute in estuaries under high urban pressure. In this work, metabolomics was used to address the main objective of this study, to evaluate the effects of two pharmaceuticals previously identified as potential concerning chemicals for fish (diazepam and irbesartan) on glass eels. An ex...
Source: Aquatic Toxicology - April 30, 2023 Category: Toxicology Authors: Iker Alvarez-Mora Val érie Bolliet Naroa Lopez-Herguedas Maitane Olivares Mathilde Monperrus Nestor Etxebarria Source Type: research
Metabolomics to study the sublethal effects of diazepam and irbesartan on glass eels (Anguilla anguilla)
Aquat Toxicol. 2023 Apr 26;259:106547. doi: 10.1016/j.aquatox.2023.106547. Online ahead of print.ABSTRACTSince glass eels are continuously exposed to contamination throughout their migratory journey in estuaries, to a certain extent the fall in the population of this endangered species might be attributed to this exposure, which is especially acute in estuaries under high urban pressure. In this work, metabolomics was used to address the main objective of this study, to evaluate the effects of two pharmaceuticals previously identified as potential concerning chemicals for fish (diazepam and irbesartan) on glass eels. An ex...
Source: Aquatic Toxicology - April 30, 2023 Category: Toxicology Authors: Iker Alvarez-Mora Val érie Bolliet Naroa Lopez-Herguedas Maitane Olivares Mathilde Monperrus Nestor Etxebarria Source Type: research
Metabolomics to study the sublethal effects of diazepam and irbesartan on glass eels (Anguilla anguilla)
Aquat Toxicol. 2023 Apr 26;259:106547. doi: 10.1016/j.aquatox.2023.106547. Online ahead of print.ABSTRACTSince glass eels are continuously exposed to contamination throughout their migratory journey in estuaries, to a certain extent the fall in the population of this endangered species might be attributed to this exposure, which is especially acute in estuaries under high urban pressure. In this work, metabolomics was used to address the main objective of this study, to evaluate the effects of two pharmaceuticals previously identified as potential concerning chemicals for fish (diazepam and irbesartan) on glass eels. An ex...
Source: Aquatic Toxicology - April 30, 2023 Category: Toxicology Authors: Iker Alvarez-Mora Val érie Bolliet Naroa Lopez-Herguedas Maitane Olivares Mathilde Monperrus Nestor Etxebarria Source Type: research
A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization – results from IQVIA™ Disease Analyzer Germany
ConclusionThis study showed that patients were able to continue ARB treatment despite the July 2018 –March 2019 recalls, although many patients needed to switch to an alternative ARB. The duration of the impact of ARB recalls appeared to be limited. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - April 24, 2023 Category: Drugs & Pharmacology Source Type: research
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study
Conclusion
The first recall notice for valsartan resulted in substantial decline in usage due to increased switching to other ARBs. Subsequent notices for losartan and irbesartan were also associated with increased switching around the time of the recall, however, overall usage trends remained unchanged. (Source: BMJ Open)
Source: BMJ Open - April 17, 2023 Category: General Medicine Authors: Eworuke, E., Shinde, M., Hou, L., Paterson, M. J., Jensen, P. B., Maro, J. C., Rai, A., Scarnecchia, D., Pennap, D., Woronow, D., Ghosh, R. E., Welburn, S., Pottegard, A., Platt, R. W., Lee, H., Bradley, M. C. Tags: Open access, Epidemiology Source Type: research
Virtual Screening of Novel 24-Dehydroxysterol Reductase ( < em > DHCR24 < /em > ) Inhibitors and the Biological Evaluation of Irbesartan in Cholesterol-Lowering Effect
Molecules. 2023 Mar 14;28(6):2643. doi: 10.3390/molecules28062643.ABSTRACTHyperlipidemia is a risk factor for the development of fatty liver and cardiovascular diseases such as atherosclerosis and coronary heart disease, and hence, cholesterol-lowering drugs are considered important and effective in preventing cardiovascular diseases. Thus, researchers in the field of new drug development are endeavoring to identify new types of cholesterol-lowering drugs. 3β-hydroxysterol-Δ(24)-reductase (DHCR24) catalyzes the conversion of desmosterol to cholesterol, which is the last step in the cholesterol biosynthesis pathway. We sp...
Source: Atherosclerosis - March 29, 2023 Category: Cardiology Authors: Haozhen Wang Ziyin Lu Yang Li Ting Liu Linlin Zhao Tianqi Gao Xiuli Lu Bing Gao Source Type: research
